Form 8-K - Current report:
SEC Accession No. 0001564590-20-046696
Filing Date
2020-10-19
Accepted
2020-10-19 08:05:28
Documents
15
Period of Report
2020-10-19
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ntla-8k_20201019.htm   iXBRL 8-K 41476
2 EX-99.1 ntla-ex991_6.htm EX-99.1 24557
3 GRAPHIC gn50lj1b4lld000001.jpg GRAPHIC 5168
4 GRAPHIC gn50lj1b4lld000002.jpg GRAPHIC 1994
  Complete submission text file 0001564590-20-046696.txt   212440

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA ntla-20201019.xsd EX-101.SCH 5768
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE ntla-20201019_lab.xml EX-101.LAB 19472
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ntla-20201019_pre.xml EX-101.PRE 11626
8 EXTRACTED XBRL INSTANCE DOCUMENT ntla-8k_20201019_htm.xml XML 3550
Mailing Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139
Business Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Filer) CIK: 0001652130 (see all company filings)

EIN.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37766 | Film No.: 201245281
SIC: 2835 In Vitro & In Vivo Diagnostic Substances